BONESUPPORT HOLDING AB (SE:BONEX)

:BONEX

BONEX

BONESUPPORT HOLDING AB

RESEARCH TOOLSreports

Want to see SE:BONEX full AI Analyst Report?

BONESUPPORT HOLDING AB (BONEX) Earnings Dates, Call Summary & Reports

Q: What is the P/E ratio of BONESUPPORT HOLDING AB stock?

The P/E ratio of {name} is N/A.

10 Followers

Earnings Data

Report Date

Jul 09, 2026

TBA (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

1.11

Last Year’s EPS

0.79

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Apr 22, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented a predominantly positive operational picture: strong underlying demand and significant constant-currency revenue growth (notably in the U.S. for CERAMENT G), high gross margins, solid adjusted profitability and robust cash generation. Strategic progress was highlighted by clinical publications, first sales in India, early spine activity, and a favorable CMS proposed ruling that could materially improve reimbursement. Offsetting risks include material currency translation headwinds that reduced reported growth, a tariff-driven margin headwind in the U.S., higher short‑term commercial and incentive costs that will press margins while investments ramp, early-stage/soft BVF spine revenues and timing uncertainty around the CERAMENT V De Novo approval. On balance, the positives (strong growth momentum, cash generation, margin levels, reimbursement progress) materially outweigh the challenges.

Company Guidance

Management reiterated guidance to keep making gradual commercial investments—including ~10 new U.S. hires and the EUROW Booster (≈SEK 10m incremental cost, ~18 months to payback)—which will weigh on near-term margins but is expected to drive sales and a gradual improvement in operating margins over time; Q1 metrics: net sales SEK 324m (+14% reported, +31% at constant exchange rates), adjusted operating result SEK 84.9m (adjusted operating margin ~26%; FX‑adjusted margin 25.5% vs 22.6% a year ago), reported operating result SEK 72m, operating cash flow SEK 75m and cash SEK 455m, gross margin 94.5%; product and market guidance included U.S. CERAMENT G sales SEK 222m (vs SEK 178m prior) with a record sequential increase of USD 2.6m, antibiotic‑eluting CERAMENT +48% LTM at CER, EUROW sales SEK 57m (+16% CER), U.S. contribution improvement SEK 25.5m to SEK 122.7m, and a note that a 15% U.S. tariff would equal a ~0.8 p.p. headwind to U.S. gross margin when fully phased in later in 2026; regulatory/ reimbursement milestones to monitor: FDA De Novo Q&A responses due by end‑August (company does not currently expect new clinical studies), possible FDA approval in 2026 (could extend into 2027), and a CMS proposed ruling (including NTAP for CERAMENT V contingent on timely FDA approval) with a final CMS decision expected late summer 2026.

Strong top-line growth (constant currency)

Net sales SEK 324 million in Q1 2026; growth of 31% at constant exchange rates versus Q1 2025 (reported growth 14% due to currency effects). Last 12 months sales growth shown as 22% reported, corresponding to 35% at constant exchange rates.

Robust U.S. momentum for CERAMENT G

U.S. sales SEK 267 million (growth 35% at constant exchange rates). CERAMENT G sales reached SEK 222 million in the quarter (vs SEK 178 million in Q1 2025, ≈+24.7%). Record sequential CERAMENT G growth of USD 2.6 million quarter-over-quarter (strongest ever).

Broad antibiotic-eluting product growth

Antibiotic-eluting CERAMENT grew 48% last 12 months at constant exchange rates; CERAMENT BVF (U.S.) last 12-month sales flat year-over-year at constant exchange rates while new spine launch is in early stages.

Profitability and strong margins

Adjusted operating result ~SEK 85 million (adjusted operating margin ~26%). Gross margin remained very high at 94.5%. FX-adjusted operating margin 25.5% in Q1 versus 22.6% in prior-year quarter (+2.9 percentage points).

Excellent cash generation and balance sheet

Operating cash flow SEK 75 million for the quarter; cash position SEK 455 million at quarter end. Reported average cash conversion since Q3 2024 is 81% and Q1 reported ahead of that average.

Regulatory and reimbursement progress

CERAMENT V De Novo process progressing with FDA questions being addressed (responses due no later than end-August). U.S. CMS proposed FY2027 IPPS ruling favorable for CERAMENT: improved payments, more specific procedure codes and proposed NTAP for CERAMENT V (conditional on timely FDA approval) — a positive validation of product value and potential to lower financial barriers to use.

Geographic expansion and clinical evidence support

EUROW sales SEK 57 million (+16% at constant exchange rates vs strong Q1 2025). First CERAMENT sales in India achieved in Q1. Two U.S. clinical publications (trauma pilot and open-fracture case series) published during the quarter supporting real-world use and adoption.

BONESUPPORT HOLDING AB (SE:BONEX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SE:BONEX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 09, 2026	2026 (Q2)	1.11 / -	0.79	―	―	―
Apr 22, 2026	2026 (Q1)	0.96 / 0.81	0.16	403.13% (+0.65)
Feb 24, 2026	2025 (Q4)	0.88 / 0.67	0.82	-18.90% (-0.15)
Oct 23, 2025	2025 (Q3)	0.80 / 0.52	0.465	11.83% (+0.05)
Jul 15, 2025	2025 (Q2)	0.74 / 0.79	0.417	89.45% (+0.37)
Apr 24, 2025	2025 (Q1)	- / 0.16	0.334	-52.10% (-0.17)
Feb 25, 2025	2024 (Q4)	- / 0.82	0.165	396.97% (+0.65)
Oct 24, 2024	2024 (Q3)	- / 0.47	3.516	-86.77% (-3.05)
Jul 11, 2024	2024 (Q2)	- / 0.42	0.08	421.25% (+0.34)
Apr 25, 2024	2024 (Q1)	- / 0.33	0.005	6580.00% (+0.33)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SE:BONEX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 22, 2026	kr257.00	kr254.00	-1.17%
Feb 24, 2026	kr180.80	kr187.40	+3.65%
Oct 23, 2025	kr255.60	kr238.40	-6.73%
Jul 15, 2025	kr296.60	kr311.60	+5.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BONESUPPORT HOLDING AB (SE:BONEX) report earnings?

BONESUPPORT HOLDING AB (SE:BONEX) is schdueled to report earning on Jul 09, 2026, TBA (Confirmed).

What is BONESUPPORT HOLDING AB (SE:BONEX) earnings time?

BONESUPPORT HOLDING AB (SE:BONEX) earnings time is at Jul 09, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of BONESUPPORT HOLDING AB stock?

The P/E ratio of BONESUPPORT HOLDING AB is N/A.

What is SE:BONEX EPS forecast?

SE:BONEX EPS forecast for the fiscal quarter 2026 (Q2) is 1.11.